Alzamend Neuro, Inc. (NASDAQ:ALZN) Stock Short Interest Report for October

Posted by Brenda Bartman on Oct 29th, 2026

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 34,177 shares, a decrease of 69.4% from the September 30th total of 111,547 shares. Based on an average daily trading volume, of 49,912 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.7% of the shares of the stock are short sold.

Alzamend Neuro Stock Performance

Shares of ALZN stock traded up $0.03 during trading on Thursday, hitting $1.22. 15,780 shares of the company were exchanged, compared to its average volume of 117,524. The firm has a market capitalization of $5.89 million, a price-to-earnings ratio of -0.53 and a beta of 0.27. Alzamend Neuro has a twelve month low of $0.84 and a twelve month high of $2.68. The business’s 50-day simple moving average is $1.55 and its 200 day simple moving average is $1.50.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last released its quarterly earnings results on Thursday, September 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.12). On average, equities analysts forecast that Alzamend Neuro will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. Kingsbury Capital Investment Advisors LLC grew its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 134.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,329,100 shares of the company’s stock after purchasing an additional 762,367 shares during the quarter. Alzamend Neuro comprises approximately 1.3% of Kingsbury Capital Investment Advisors LLC’s holdings, making the stock its 18th largest holding. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.00.

Read Our Latest Stock Report on ALZN

Alzamend Neuro Company Profile

(Get Free Report)

Alzamend Neuro, Inc (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and neuropsychiatric diseases, with an emphasis on Alzheimer’s disease and related dementia. The company’s research is intended to address cognitive decline and other disease-related symptoms through therapies designed to affect biological processes associated with brain function.

Alzamend Neuro’s lead development program is AL001, an investigational lithium-based product candidate being studied for potential use in the treatment of Alzheimer’s disease.